The global leukemia therapeutics treatment market is expected to grow at a CAGR of 6.6% during the forecast period (2025–2035). Factors such as the rising prevalence of leukemia, increasing adoption ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This 'first ...
Zacks Investment Research on MSN7d
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...
Tiffany Meng, PharmD, an oncology pharmacist, UCSF Health, discusses how pharmacists help mitigate financial toxicity for ...
Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...
The FDA has approved 2 biosimilars, denosumab-bmwo (CT-P41; Stoboclo) and (Osenvelt), for all indications of their respective reference products (Prolia) and (Xgeva), Celltrion stated in a news ...
To explore the valuable insights in the HEOR Services Market report, you can easily download a sample PDF of the report- HE ...
Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...
Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback